Alternative | Incremental cost-effectiveness ratioa | Incremental net benefits ($) | |||||||
---|---|---|---|---|---|---|---|---|---|
LOW | LMI | UMI | HIGH | LOW | LMI | UMI | HIGH | All | |
OPV23 cessation in 2017 | CLS | CLS | CLS | CLS | 0.3 | 3.0 | 2.7 | 1.3 | 7.3 |
OPV123 cessation in 2018 | CLS | CLS | CLS | 1.9 | 300 | 660 | 190 | −8.6 | 1,100 |
OPV123 cessation in 2019 | Dominated | Dominated | Dominated | Dominated | −0.3 | −2.6 | −1.6 | 0 | −4.6 |
OPV123 cessation in 2019 with tOPV-only from 2017 | Dominated | Dominated | Dominated | Dominated | −0.3 | −2.5 | −1.6 | 0 | −4.5 |
OPV123 cessation in 2019 with IPV added from 2018 | CSLC | CSLC | CSLC | Dominated | 110 | 370 | 380 | 0 | 860 |